Prognostic value of vascular endothelial growth factor expression in resected gastric cancer

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 7, 2012, Pages 3089-3097

  Liu, Lei ^a   Ma, Xue Lei ^a   Xiao, Zhi Lan ^a   Li, Mei ^a   Cheng, Si Hang ^a   Wei, Yu Quan ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Gastric cancer; Growth factors and signal transduction; Prognosis; VEGF

Indexed keywords

EID: 84873602673     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.7.3089     Document Type: Article

References (78)

1. Akdogan R, Aydin F, Ozdemir F, et al (2006). The effects of VEGF and VEGFR-2 on survival in patients with gastric cancer. J Exp Clin Cancer Res, 25, 83-8.
2. Altman DG, Deeks JJ, Higgins JP, Thompson SG (2003). Measuring inconsistency in meta-analyses. BMJ, 327, 557-60.
3. Altman DG, McShane LM, Sauerbrei W, et al (2006). Reporting recommendations for tumor marker prognostic studies (remark). Exp Oncol, 28, 99-105.
4. Amaya H, Matsumura M, Shimomatsuya T, Tanigawa N (1997). Correlation between expression of vascular endothelial growth factor and tumor vascularity, and patient outcome in human gastric carcinoma. J Clin Oncol, 15, 826-32.
5. Aoyagi K, Kouhuji K, Yano S, et al (2005). VEGF significance in peritoneal recurrence from gastric cancer. Gastric Cancer, 8, 155-63.
6. Bai M, Goussia A, Skarlos DV, et al (2007). Expression of a molecular marker panel as a prognostic tool in gastric cancer patients treated postoperatively with docetaxel and irinotecan. A study of the Hellenic Cooperative Oncology Group. Anticancer Res, 27, 2973-83.
7. Bates DO, Hillman NJ, Neal CR, Pocock TM, Williams B (2002). Regulation of microvascular permeability by vascular endothelial growth factors. J Anat, 200, 581-97.
8. Bazas VM, Demash DV, Galakhin KO, Lukyanova NY, Myasoedov DV (2008). Relation between cell-to-celladhesion and angiogenesis and clinico-morphological prognostic factors in patients with gastric cancer. Exp Oncol, 30, 235-9.
9. Berse B, Brown LF, Van de Water L, et al (1992). Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages, and tumors. Mol Biol Cell, 3, 211-20.
10. Bray F, Center MM, Jemal A, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90.
11. Burdett S, Ghersi D, Stewart LA, Sydes MR, Tierney JF (2007). Practical methods for incorporating summary time-to-event data into meta-analysis. Trials, 8, 16.
12. Cao W, Mo M, Wang X, et al (2010). VEGF and cortactin expression are independent predictors of tumor recurrence following curative resection of gastric cancer. J Surg Oncol, 102, 325-30.
13. Chen J, Li T, Wu Y, et al (2011). Prognostic significance of vascular endothelial growth factor expression in gastric carcinoma: a meta-analysis. J Cancer Res Clin Oncol, 137, 1799-812.
14. Chen XC, Gou HF, Zhu J, et al (2011). Expressions of COX-2 and VEGF-C in gastric cancer: correlations with lymphangiogenesis and prognostic implications. J Exp Clin Cancer Res, 30, 14.
15. Chen XC, Gou HF, Zhu J, et al (2011). Expressions of COX-2 and VEGF-C in gastric cancer: correlations with lymphangiogenesis and prognostic implications. J Exp Clin Cancer Res, 30, 14.
16. Choi JH, Oh YH, Park YW, et al (2008). Correlation of vascular endothelial growth factor-D expression and VEGFR-3- positive vessel density with lymph node metastasis in gastric carcinoma. J Korean Med Sci, 23, 592-7.
17. Clark JW, Duda DG, Jain RK, Loeffler JS (2006). Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol, 3, 24-40.
18. Cunha IW, Ioannidis JP, Kyzas PA (2005). Prognostic significance of vascular endothelial growth factor immunohistochemical expression in head and neck squamous cell carcinoma: a meta-analysis. Clin Cancer Res, 11, 1434-40.
19. Da MX, Wang J, Wu XT, et al (2008). Expression of cyclooxygenase-2 and vascular endothelial growth factor-C correlates with lymphangiogenesis and lymphatic invasion in human gastric cancer. Arch Med Res, 39, 92-9.
20. Deguchi K, Ichikawa D, Soga K, et al (2010). Clinical significance of vascular endothelial growth factors C and D and chemokine receptor CCR7 in gastric cancer. Anticancer Res, 30, 2361-6.
21. Deguchi K, Ichikawa D, Soga K, et al (2010). Clinical significance of vascular endothelial growth factors C and D and chemokine receptor CCR7 in gastric cancer. Anticancer Res, 30, 2361-6.
22. Deng J, Liang H, Sun D, et al (2009). Vascular endothelial growth factor-D is correlated with hepatic metastasis from gastric cancer after radical gastrectomy. Surgery, 146, 896-905.
23. Deng MH, Dong WG, Qiu WS, Wang TB (2007). Association of serum vascular endothelial growth factor-C and lymphatic vessel density with lymph node metastasis and prognosis of patients with gastric cancer. World J Gastroenterol, 13, 1794-8.
24. Detmar M, Wissmann C (2006). Pathways targeting tumor lymphangiogenesis. Clin Cancer Res, 12, 6865-8.
25. Detmar M, Wissmann C (2006). Pathways targeting tumor lymphangiogenesis. Clin Cancer Res, 12, 6865-8.
26. Ding S, Li C, Lin S, et al (2007). Distinct roles of VEGF-A and VEGF-C in tumour metastasis of gastric carcinoma. Oncol Rep, 17, 369-75.
27. Ding S, Li C, Lin S, et al (2007). Distinct roles of VEGF-A and VEGF-C in tumour metastasis of gastric carcinoma. Oncol Rep, 17, 369-75.
28. Doki Y, Fujiwara Y, Urano N, et al (2006). Overexpression of hypoxia-inducible factor-1 alpha in gastric adenocarcinoma. Gastric Cancer, 9, 44-9.
29. Elizalde I, Metges JP, Vidal O, et al (2009). High preoperative serum vascular endothelial growth factor levels predict poor clinical outcome after curative resection of gastric cancer. Br J Surg, 96, 1443-51.
30. Endo Y, Fujita H, Yonemura Y, et al (1999). Role of vascular endothelial growth factor C expression in the development of lymph node metastasis in gastric cancer. Clin Cancer Res, 5, 1823-9.
31. Feldman AL, Paciotti GF, Tamarkin L, et al (2000). Serum endostatin levels are elevated and correlate with serum vascular endothelial growth factor levels in patients with stage IV clear cell renal cancer. Clin Cancer Res, 6, 4628-34.
32. Ferrara N, Gerber HP, Hillan KJ, Novotny W (2004). Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov, 3, 391-400.
33. Ferrara N, Houck K, Jakeman L, Leung DW (1992). Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocr Rev, 13, 18-32.
34. Ferraraccio F, Lieto E, Orditura M, et al (2008). Expression of vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) is an independent prognostic indicator of worse outcome in gastric cancer patients. Ann Surg Oncol, 15, 69-79.
35. Fondevila C, Fuster J, Metges JP, et al (2004). p53 and VEGF expression are independent predictors of tumour recurrence and survival following curative resection of gastric cancer. Br J Cancer, 90, 206-15.
36. Fujioka S, Ishibashi Y, Shida A, et al (2005). Prognostic significance of vascular endothelial growth factor D in gastric carcinoma. World J Surg, 29, 1600-7.
37. Fujioka S, Kobayashi K, Shida A, et al (2006). Expression of vascular endothelial growth factor (VEGF)-C and -D in gastric carcinoma. Int J Clin Oncol, 11, 38-43.
38. Fujisaki K, Matsuo K, Mitsuyama K, Tanikawa K, Toyonaga A (1998). Circulating vascular endothelial growth factor in patients with colorectal cancer. Am J Gastroenterol, 93, 249-52.
39. Ghaneh P, Neoptolemos JP, Smith RA, Tang J, Tudur-Smith C (2011). Meta-analysis of immunohistochemical prognostic markers in resected pancreatic cancer. Br J Cancer, 104, 1440-51.
40. Ghaneh P, Neoptolemos JP, Smith RA, Tang J, Tudur-Smith C (2011). Meta-analysis of immunohistochemical prognostic markers in resected pancreatic cancer. Br J Cancer, 104, 1440-51.
41. Gores GJ, Kurtz DM, Roberts LR, Schoenleber SJ, Talwalkar JA (2009). Prognostic role of vascular endothelial growth factor in hepatocellular carcinoma: systematic review and meta-analysis. Br J Cancer, 100, 1385-92.
42. Han FH, He YL, Li HM, Zhan WH, Zheng DH (2010). The effect of the expression of vascular endothelial growth factor (VEGF)-C and VEGF receptor-3 on the clinical outcome in patients with gastric carcinoma. Eur J Surg Oncol, 36, 1172-9.
43. Han FH, He YL, Li HM, Zhan WH, Zheng DH (2010). The effect of the expression of vascular endothelial growth factor (VEGF)-C and VEGF receptor-3 on the clinical outcome in patients with gastric carcinoma. Eur J Surg Oncol, 36, 1172-9.
44. Hattori N, Kido S, Kitadai Y, et al (2001). Interleukin 8 and vascular endothelial growth factor -- prognostic factors in human gastric carcinomas. Eur J Cancer, 37, 1482-7.
45. Hu NZ, Shi H, Xie HJ, Xu JM (2003). Prognostic significance of expression of cyclooxygenase-2 and vascular endothelial growth factor in human gastric carcinoma. World J Gastroenterol, 9, 1421-6.
46. Hutton JL, Marson AG, Smith CT, Williamson PR (2002). Aggregate data meta-analysis with time-to-event outcomes. Stat Med, 21, 3337-51.
47. Ichikura T, Mochizuki H, Ohkura E, Tomimatsu S (2001). Prognostic significance of the expression of vascular endothelial growth factor (VEGF) and VEGF-C in gastric carcinoma. J Surg Oncol, 78, 132-7.
48. Iida S, Kolev Y, Uetake H, et al (2007). Prognostic significance of VEGF expression in correlation with COX-2, microvessel density, and clinicopathological characteristics in human gastric carcinoma. Ann Surg Oncol, 14, 2738-47.
49. Ikeguchi M, Oka S, Saito H, et al (1999). The expression of vascular endothelial growth factor and proliferative activity of cancer cells in gastric cancer. Langenbecks Arch Surg, 384, 264-70.
50. Itakura J, Kono K, Takahashi A, et al (2002). Correlation of vascular endothelial growth factor-C expression with tumor-infiltrating dendritic cells in gastric cancer. Oncology, 62, 121-7.
51. Joensuu H, Mattson K, Ruotsalainen T, Salven P (1998). High pre-treatment serum level of vascular endothelial growth factor (VEGF) is associated with poor outcome in small-cell lung cancer. Int J Cancer, 79, 144-6.
52. Jons T, Juttner S, Wissmann C, et al (2006). Vascular endothelial growth factor-D and its receptor VEGFR-3: two novel independent prognostic markers in gastric adenocarcinoma. J Clin Oncol, 24, 228-40.
53. Joo SY, Joo YE, Sohn YH, et al (2002). The role of vascular endothelial growth factor (VEGF) and p53 status for angiogenesis in gastric cancer. Korean J Intern Med, 17, 211-9.
54. Kakeji Y, Koga T, Sumiyoshi Y, et al (2002). Clinical significance of vascular endothelial growth factor expression in gastric cancer. J Exp Clin Cancer Res, 21, 125-9.
55. Kang SM, Maeda K, Ogawa M, et al (1997). Combined analysis of vascular endothelial growth factor and platelet-derived endothelial cell growth factor expression in gastric carcinoma. Int J Cancer, 74, 545-50.
56. Kang SM, Maeda K, Onoda N, et al (1998). Expression of p53 and vascular endothelial growth factor associated with tumor angiogenesis and prognosis in gastric cancer. Oncology, 55, 594-9.
57. Kang SM, Maeda K, Onoda N, et al (1999). Vascular endothelial growth factor expression in preoperative biopsy specimens correlates with disease recurrence in patients with early gastric carcinoma. Cancer, 86, 566-71.
58. Karayiannakis AJ, Polychronidis A, Syrigos KN, et al (2002). Circulating VEGF levels in the serum of gastric cancer patients: correlation with pathological variables, patient survival, and tumor surgery. Ann Surg, 236, 37-42.
59. Kerbel RS (2008). Tumor angiogenesis. N Engl J Med, 358, 2039-49.
60. Kim JG, Lee SJ, Sohn SK, et al (2009). No association of vascular endothelial growth factor-A (VEGF-A) and VEGF-C expression with survival in patients with gastric cancer. Cancer Res Treat, 41, 218-23.
61. Kim JG, Lee SJ, Sohn SK, et al (2009). No association of vascular endothelial growth factor-A (VEGF-A) and VEGF-C expression with survival in patients with gastric cancer. Cancer Res Treat, 41, 218-23.
62. Kimura H, Konishi K, Nukui T, et al (2001). Prognostic significance of expression of thymidine phosphorylase and vascular endothelial growth factor in human gastric carcinoma. J Surg Oncol, 76, 31-6.
63. Kitadai Y, Takahashi R, Tanaka S, et al (2003). Expression of vascular endothelial growth factor and angiogenesis in gastrointestinal stromal tumor of the stomach. Oncology, 64, 266-74.
64. Kobayashi O, Tsuburaya A, Yoshikawa T, et al (2000). Plasma concentrations of VEGF and bFGF in patients with gastric carcinoma. Cancer Lett, 153, 7-12.
65. Kondo A, Saito H, Tsujitani S, et al (1999). Expression of vascular endothelial growth factor correlates with hematogenous recurrence in gastric carcinoma. Surgery, 125, 195-201.
66. Kondo S, Toi M, Yamamoto Y, et al (1996). Concentrations of vascular endothelial growth factor in the sera of normal controls and cancer patients. Clin Cancer Res, 2, 821-6.
67. Kraft A, Ochs A, Weindel K, et al (1999). Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease. Cancer, 85, 178-87.
68. Kuwano H, Shimura T, Tsutsumi S, et al (2005). Vascular endothelial growth factor C (VEGF-C) expression in pT2 gastric cancer. Hepatogastroenterology, 52, 629-32.
69. Lau C, Ng IO, Poon RT, et al (2001). Serum vascular endothelial growth factor predicts venous invasion in hepatocellular carcinoma: a prospective study. Ann Surg, 233, 227-35.
70. Li G, Wu J, Zhou Y, et al (2010). Clinicopathological significance of E-cadherin, VEGF, and MMPs in gastric cancer. Tumour Biol, 31, 549-58.
71. Lv XJ, Wang J, Zhan P, et al (2009). Prognostic value of vascular endothelial growth factor expression in patients with lung cancer: a systematic review with meta-analysis. J Thorac Oncol, 4, 1094-103.
72. Ma J, Ru GQ, Zhang L, Zhao ZS (2006). Correlative studies on uPA mRNA and uPAR mRNA expression with vascular endothelial growth factor, microvessel density, progression and survival time of patients with gastric cancer. World J Gastroenterol, 12, 3970-6.
73. Masselou K, Papastratis G, Tsirlis TD, et al (2008). Circulating lymphangiogenic growth factors in gastrointestinal solid tumors, could they be of any clinical significance. World J Gastroenterol, 14, 2691-701.
74. Park JM, Park KH, Seo HY, et al (2010). Prognostic significance of serum vascular endothelial growth factor per platelet count in unresectable advanced gastric cancer patients. Jpn J Clin Oncol, 40, 1147-53.
75. Parmar MK, Stewart L, Torri V (1998). Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med, 17, 2815-34.
76. Pera M, Soriano-Izquierdo A, Vidal O, et al (2008). Positive VEGF immunostaining independently predicts poor prognosis in curatively resected gastric cancer patients: results of a study assessing a panel of angiogenic markers. J Gastrointest Surg, 12, 1005-14.
77. Wang J, Yang S, Zhang H, et al (2011). Aurora-A as an independent molecular prognostic marker in gastric cancer. Oncol Rep, 26, 23-32.
78. Yang Q, Ye ZY, Zhang JX, et al (2010). Expression of matrix metalloproteinase-9 mRNA and vascular endothelial growth factor protein in gastric carcinoma and its relationship to its pathological features and prognosis. Anat Rec (Hoboken), 293, 2012-9.